Published in Depress Anxiety on June 11, 2012
The expanding evidence base for rTMS treatment of depression. Curr Opin Psychiatry (2013) 1.29
Brain stimulation treatments for depression. World J Biol Psychiatry (2014) 1.05
Where in the brain is depression? Curr Psychiatry Rep (2012) 0.97
The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder. Front Hum Neurosci (2013) 0.92
The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul (2016) 0.88
Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis. Depress Res Treat (2014) 0.86
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Can J Psychiatry (2016) 0.83
Transcranial magnetic stimulation for geriatric depression: Promises and pitfalls. World J Psychiatry (2015) 0.81
Transcranial magnetic stimulation for the treatment of major depression. Neuropsychiatr Dis Treat (2015) 0.80
5Hz Repetitive transcranial magnetic stimulation to left prefrontal cortex for major depression. J Affect Disord (2015) 0.80
Seizure Induced by Deep Transcranial Magnetic Stimulation in an Adolescent with Depression. J Child Adolesc Psychopharmacol (2016) 0.78
Reply to the letter to the editor by George et Al. World J Biol Psychiatry (2014) 0.75
Use of transcranial direct current stimulation for the treatment of auditory hallucinations of schizophrenia - a systematic review. Neuropsychiatr Dis Treat (2017) 0.75
Transcranial magnetic stimulation for treatment-resistant depression: Naturalistic treatment outcomes for younger versus older patients. J Affect Disord (2017) 0.75
Ultrasound modulates ion channel currents. Sci Rep (2016) 0.75
Repetitive transcranial magnetic stimulation induced hypomanic symptoms in a woman with a history of electroconvulsive therapy induced mania: a case report. F1000Res (2013) 0.75
Magnetic Resonance Therapy Improves Clinical Phenotype and EEG Alpha Power in Posttraumatic Stress Disorder. Trauma Mon (2015) 0.75
Targeting Neural Endophenotypes of Eating Disorders with Non-invasive Brain Stimulation. Front Neurosci (2016) 0.75
Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives. Biol Psychiatry (2017) 0.75
A naturalistic, multi-site study of repetitive transcranial magnetic stimulation therapy for depression. J Affect Disord (2016) 0.75
Treatment of Bipolar Depression with Deep TMS (dTMS): Results from a Double-Blind, Randomized, Parallel Group, Sham-Controlled Clinical Trial. Neuropsychopharmacology (2017) 0.75
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry (2007) 5.59
Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol (2006) 5.48
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry (2002) 3.47
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry (2011) 3.34
Randomized controlled trial of trigeminal nerve stimulation for drug-resistant epilepsy. Neurology (2013) 2.62
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A (2003) 2.56
Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry (2002) 2.39
Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome. Evid Based Complement Alternat Med (2007) 2.22
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry (2005) 1.99
Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry (2008) 1.89
Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry (2004) 1.89
Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol (2008) 1.87
American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry (2007) 1.79
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res (2002) 1.78
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry (2002) 1.67
Frontal lobe gray matter density decreases in bipolar I disorder. Biol Psychiatry (2004) 1.65
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry (2002) 1.65
Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol (2004) 1.65
Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord (2006) 1.59
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry (2007) 1.54
Linking disease symptoms and subtypes with personalized systems-based phenotypes: a proof of concept study. Brain Behav Immun (2012) 1.53
A web-based data management system to improve care for depression in a multicenter clinical trial. Psychiatr Serv (2002) 1.48
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology (2005) 1.47
Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun (2004) 1.44
A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry (2005) 1.43
A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry (2006) 1.42
Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry (2004) 1.42
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol (2004) 1.40
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry (2007) 1.40
Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res (2009) 1.40
Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol (2010) 1.29
A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry (2004) 1.26
Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics (2004) 1.21
Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry (2006) 1.20
Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res (2009) 1.18
Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry (2004) 1.18
A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord (2004) 1.15
Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord (2010) 1.15
Transcranial magnetic stimulation reduces pain in patients with major depression: a sham-controlled study. J Nerv Ment Dis (2007) 1.15
The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. Sleep (2003) 1.14
Biomarkers to predict antidepressant response. Curr Psychiatry Rep (2010) 1.14
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry (2007) 1.14
Trigeminal nerve stimulation in major depressive disorder: first proof of concept in an open pilot trial. Epilepsy Behav (2011) 1.11
fMRI activation in the amygdala and the orbitofrontal cortex in unmedicated subjects with major depressive disorder. Psychiatry Res (2010) 1.10
Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology (2010) 1.10
Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. J Psychiatr Res (2009) 1.09
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin (2007) 1.09
A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol (2004) 1.08
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul (2010) 1.07
Trigeminal nerve stimulation: seminal animal and human studies for epilepsy and depression. Neurosurg Clin N Am (2011) 1.04
Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. Clin Neurophysiol (2004) 1.03
Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord (2004) 1.02
Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol (2009) 1.01
Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry (2008) 1.01
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. J Clin Psychiatry (2002) 1.01
Rapid cycling bipolar disorder--diagnostic concepts. Bipolar Disord (2008) 1.00
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry (2007) 0.99
Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. Am J Psychiatry (2008) 0.96
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry (2006) 0.96
Basal ganglia shape alterations in bipolar disorder. Am J Psychiatry (2006) 0.96
Adjunctive use of repetitive transcranial magnetic stimulation in depressed adolescents: a prospective, open pilot study. J Clin Psychiatry (2011) 0.95
Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul (2012) 0.95
Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. Clin Neurophysiol (2003) 0.94
Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J Consult Clin Psychol (2004) 0.94
Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry (2008) 0.93
A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci (2009) 0.93
Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology (Berl) (2004) 0.93
The occurrence of cavum septi pellucidi enlargement is increased in bipolar disorder patients. Bipolar Disord (2007) 0.93
Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry (2006) 0.93
White matter injury, neural connectivity and the pathophysiology of psychiatric disorders. Dev Neurosci (2002) 0.93
Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry (2007) 0.93
Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clin Neurophysiol (2003) 0.92
The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder. Front Hum Neurosci (2013) 0.92
Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry (2003) 0.91
An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia. Psychiatry Res (2009) 0.91
A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res (2013) 0.90
The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders. Depress Anxiety (2008) 0.90
Protein kinase C and phospholipase C activity and expression of their specific isozymes is decreased and expression of MARCKS is increased in platelets of bipolar but not in unipolar patients. Neuropsychopharmacology (2002) 0.90
Brain electrical source differences between depressed subjects and healthy controls. Brain Topogr (2008) 0.89
Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression. Clin Neurophysiol (2009) 0.89
Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol (2007) 0.88
Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry (2005) 0.87
Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression. PLoS One (2012) 0.87
A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol (2006) 0.87
Relationship between medical student perceptions of mistreatment and mistreatment sensitivity. Med Teach (2012) 0.86
Baroreflex mechanisms in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.86
Divalproex sodium for pediatric mixed mania: a 6-month prospective trial. Bipolar Disord (2005) 0.86
A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol (2003) 0.86
A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry (2007) 0.86
Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care (2008) 0.86
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry (2003) 0.86
A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry (2014) 0.86